Tasatargil Arda, Sadan Gulay
Department of Pharmacology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Anesth Analg. 2004 Jan;98(1):185-192. doi: 10.1213/01.ANE.0000093250.59364.EB.
To test our hypothesis that the abnormally small efficacy of mu-opioid agonists in diabetic rats may be due to functional changes in the L-arginine/nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway, we evaluated the effects of N-iminoethyl-L-ornithine, methylene blue, and 3-morpholino-sydnonimine on [D-Ala(2), NMePhe(4), Gly-ol(5)]enkephalin (DAMGO)-induced antinociception in both streptozotocin (STZ)-diabetic and nondiabetic rats. Animals were rendered diabetic by an injection of STZ (60 mg/kg intraperitoneally). Antinociception was evaluated by the formalin test. The mu-opioid receptor agonist DAMGO (1 microg per paw) suppressed the agitation response in the second phase. The antinociceptive effect of DAMGO in STZ-diabetic rats was significantly less than in nondiabetic rats. N-Iminoethyl-L-ornithine (100 microg per paw), an NO synthase inhibitor, or methylene blue (500 microg per paw), a guanylyl cyclase inhibitor, significantly decreased DAMGO-induced antinociception in both diabetic and nondiabetic rats. Furthermore, 3-morpholino-sydnonimine (200 microg per paw), an NO donor, enhanced the antinociceptive effect of DAMGO in nondiabetic rats but did not change in diabetic rats. These results suggest that the peripheral antinociceptive effect of DAMGO may result from activation of the L-arginine/NO/cGMP pathway and dysfunction of this pathway; also, events that are followed by cGMP activation may have contributed to the demonstrated poor antinociceptive response of diabetic rats to mu-opioid agonists.
This is the first study on the role of the nitric oxide (NO)/cyclic guanosine monophosphate pathway on [D-Ala(2), NMePhe(4), Gly-ol(5)]enkephalin (DAMGO)-induced peripheral antinociception and the effect of diabetes on this pathway. The study suggests a possible role of DAMGO as a peripherally-acting analgesic drug.
为验证我们的假设,即μ阿片受体激动剂在糖尿病大鼠中疗效异常低下可能是由于L-精氨酸/一氧化氮(NO)/环磷酸鸟苷(cGMP)途径的功能改变所致,我们评估了N-亚氨基乙基-L-鸟氨酸、亚甲蓝和3-吗啉代西多胺对[D-丙氨酸(2),N-甲基苯丙氨酸(4),甘氨醇(5)]脑啡肽(DAMGO)诱导的链脲佐菌素(STZ)糖尿病大鼠和非糖尿病大鼠镇痛作用的影响。通过腹腔注射STZ(60mg/kg)使动物患糖尿病。通过福尔马林试验评估镇痛作用。μ阿片受体激动剂DAMGO(每只爪1μg)抑制了第二阶段的激惹反应。DAMGO在STZ糖尿病大鼠中的镇痛作用明显低于非糖尿病大鼠。NO合酶抑制剂N-亚氨基乙基-L-鸟氨酸(每只爪100μg)或鸟苷酸环化酶抑制剂亚甲蓝(每只爪500μg)显著降低了DAMGO在糖尿病和非糖尿病大鼠中诱导的镇痛作用。此外,NO供体3-吗啉代西多胺(每只爪200μg)增强了DAMGO在非糖尿病大鼠中的镇痛作用,但在糖尿病大鼠中无变化。这些结果表明,DAMGO的外周镇痛作用可能源于L-精氨酸/NO/cGMP途径的激活以及该途径的功能障碍;此外,cGMP激活后发生的事件可能导致了糖尿病大鼠对μ阿片受体激动剂镇痛反应不佳。
这是第一项关于一氧化氮(NO)/环磷酸鸟苷途径对[D-丙氨酸(2),N-甲基苯丙氨酸(4),甘氨醇(5)]脑啡肽(DAMGO)诱导的外周镇痛作用的作用以及糖尿病对该途径影响的研究。该研究提示DAMGO作为一种外周作用镇痛药的可能作用。